Precision Business Insights
Portfolio

 

Research Reports

Noninvasive Prenatal Testing Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Global Noninvasive Prenatal Testing Market

 

By Product Type (Instruments and Consumables), By End User (Hospitals, Maternity Clinics, and Diagnostic Centers), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

 

Global noninvasive prenatal testing market was valued at US$ XX Mn in 2017 and expected to grow at XX% Compound Annual Growth Rate (CAGR) from 2018 to 2024

 

Market Outline: Noninvasive Prenatal Testing Market

Noninvasive prenatal testing is a new type of genetic testing that is used to screen birth defects and inherited diseases. This test is also known as the cell-free DNA screening. The procedures include both non-invasive techniques and invasive techniques. In non-invasive techniques, serum screening and ultrasonography are included. Whereas, in invasive techniques amniocentesis and chorionic villus sampling are included. Most of the healthcare professionals prefer the non-invasive techniques over invasive, as the invasive techniques have higher risk quotient, also sometimes leads to fetal loss. Noninvasive prenatal testing are the innovative testing procedures that uses cell-free circulating fetal DNA in the maternal serum to screen for more common fetal aneuploidies, such as trisomy 21, trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome), and monosomy X (Turner syndrome). Increasing prevalence of these genetic disorders are likely to drive the market for non-invasive prenatal testing over the forecast period.

 

Market Dynamics: Noninvasive Prenatal Testing Market

The rising awareness among parents, adoption toward IVF procedures is driving the market. In birth outcomes such as birth defects, newborn weight, and multiple births, maternal age plays a major role. The average age at which women are giving first birth has been increasing. As per Centre for Disease Control and Prevention (CDC) report, the mean age of a women at first birth was 25.8 years in 2012, and it has increased to 26 years in 2013, in the U.S. In addition to that, according to the World Health Organization (WHO), about 3,000 to 5,000 children are born with chromosome disorder, approximately 60%-80% of the children with Down syndrome have hearing deficit, and 40%-45% have congenital heart disease. The rise in the prevalence of these genetic disorders is likely to drive the market for non-invasive prenatal testing market.

 

Market Scope: Noninvasive Prenatal Testing Market

The noninvasive prenatal testing market is segmented based on the product type, end user and region

Based on the product type, the market is segmented into the following:

  • Instruments
    • Microarrays
    • Ultrasound Devices
    • NGS Systems
    • PCR Instruments
    • Other Instruments
  • Consumables
    • Assay Kits &Reagents
    • Disposables

Based on the end user, the market is segmented into the following:

  • Hospitals
  • Maternity Clinics
  • Diagnostic Centers

 

Regional Analysis:  Noninvasive Prenatal Testing Market

Geographically, global noninvasive prenatal testing market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominates the noninvasive prenatal testing market due to growing adoption of advanced diagnostics in the region and increase in the access to various prenatal testing procedures. North America is expected to hold the largest revenue share over the forecast period. Followed by the North America are the regions of Europe and Asia Pacific. The countries such as India and China are predicted to drive the market in Asia-Pacific region due to favorable population demographics.

 

Competition Assessment: Noninvasive Prenatal Testing Market

Some of the players in the global noninvasive prenatal testing market include:

  • PerkinElmer, Inc. (U.S.)
  • QIAGEN N.V. (Germany)
  • Becton, Dickinson and Company (U.S)
  • Agilent Technologies, Inc. (U.S.)
  • Beijing Genomics Institute (China)
  • GE Healthcare (U.S.)
  • Koninklijke Philips N.V. (Netherlands)
  • Illumina, Inc. (U.S.)
  • Thermo Fisher Scientific, Inc. (U.S.)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Pacific Biosciences of California, Inc. (U.S.)

 

Notable Market Developments: Noninvasive Prenatal Testing Market

  • In February 2018, BD (Becton, Dickinson and Company) announced the commercial availability of the CE-IVD marked PAXgene Blood ccfDNA tube within the European Economic Area and Switzerland (Western Europe)

 

Key Features of the Report:

  • The report covers exhaustive regional information, that includes North America (The USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, Venezuela, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
  • The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenari0
  • PerkinElmer, Inc. (U.S.)
  • QIAGEN N.V. (Germany)
  • Becton, Dickinson and Company (U.S)
  • Agilent Technologies, Inc. (U.S.)
  • Beijing Genomics Institute (China)
  • GE Healthcare (U.S.)
  • Koninklijke Philips N.V. (Netherlands)
  • Illumina, Inc. (U.S.)
  • Thermo Fisher Scientific, Inc. (U.S.)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Pacific Biosciences of California, Inc. (U.S.)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements